Channer K S, McLean K A, Lawson-Matthew P, Richardson M
Department of Cardiology, Royal Hallamshire Hospital, Sheffield.
Br Heart J. 1994 Feb;71(2):146-50. doi: 10.1136/hrt.71.2.146.
(a) To test the hypothesis that a fixed 3 day course of the combination of a thiazide and loop diuretic is as effective as more prolonged treatment in the management of severe resistant cardiac failure. (b) To compare two thiazide diuretics (bendrofluazide and metolazone) in combination with loop diuretics in the treatment of severe resistant cardiac failure.
Randomised study with a 2 x 2 factorial design.
Provincial teaching hospital.
33 consecutive patients (40 episodes) admitted with severe congestive cardiac failure (New York Heart Association class III or IV) unresponsive to intravenous loop diuretics for 48 hours.
Change in daily weight and serum electrolytes and clinical improvement in heart failure.
Diuresis was established during 37 of 40 episodes; of the rest two patients died in hospital. On 36 occasions improvement was sufficient to allow discharge from hospital. Median (range) maximal weight loss was -5.05 (-11.3 to 1.6) kg after the addition of bendrofluazide and -5.6 (-12.2 to 4.8) kg after the addition of metolazone (NS). Area under the body weight loss against time curves showed no significant difference between the two thiazide diuretics. Median (range) maximal weight loss after three days of treatment was -5.4 (-12.2 to 4.8) kg and -5.5 (-10.3 to 1) kg after a more prolonged course of median (range) 5.6 (1 to 13) days (NS). Area under the body weight loss time curves showed no significant difference between the two durations of treatment. Bendrofluazide was associated with fewer electrolyte disturbances.
Bendrofluazide and metolazone were equally effective in establishing a diuresis in patients with severe congestive cardiac failure resistant to loop diuretics. A fixed three day course of the combination was as effective as a longer course.
(a) 检验以下假设:噻嗪类利尿剂与襻利尿剂联合使用的固定3日疗程在治疗严重顽固性心力衰竭方面与更长疗程的治疗效果相同。(b) 比较两种噻嗪类利尿剂(苄氟噻嗪和美托拉宗)与襻利尿剂联合用于治疗严重顽固性心力衰竭的效果。
采用2×2析因设计的随机研究。
省级教学医院。
33例连续入院的严重充血性心力衰竭患者(40个病例)(纽约心脏协会心功能III级或IV级),对静脉注射襻利尿剂48小时无反应。
每日体重和血清电解质的变化以及心力衰竭的临床改善情况。
40个病例中有37个病例实现了利尿;其余两名患者在医院死亡。有36次病情改善到足以出院。添加苄氟噻嗪后,体重最大减轻中位数(范围)为-5.05(-11.3至1.6)kg,添加美托拉宗后为-5.6(-12.2至4.8)kg(无显著差异)。体重减轻量随时间变化曲线下的面积显示,两种噻嗪类利尿剂之间无显著差异。治疗3天后体重最大减轻中位数(范围)为-5.4(-12.2至4.8)kg,中位数(范围)为5.6(1至13)天的更长疗程后为-5.5(-10.3至1)kg(无显著差异)。体重减轻时间曲线下的面积显示,两种治疗持续时间之间无显著差异。苄氟噻嗪引起的电解质紊乱较少。
苄氟噻嗪和美托拉宗在对襻利尿剂耐药的严重充血性心力衰竭患者中建立利尿方面同样有效。联合使用的固定3日疗程与更长疗程的效果相同。